Spectral Medical (Edtxf) (TSE:EDT) has released an update.
Spectral Medical Inc. has reported progress in the first quarter of 2024 with 106 patients enrolled in the Tigris trial, aiming for a target of 150 to advance towards FDA submission for its sepsis treatment. The company has also reinforced its collaboration with Baxter, extending their commercial partnership to ten years post-FDA approval. With recent financing, Spectral is poised to complete Tigris trial enrollment, bolstered by the addition of new trial sites and focused clinical support.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.
